据报道,γ-氨基丁酸A型受体(GABAAR)与癫痫的发病机理和慢性癫痫的复发有关。GABRA1和GABRA6基因多态性可能导致癫痫和多药耐药的高风险。但结果相互矛盾。我们旨在使用荟萃分析评估GABRA1rs2279020和GABRA6rs3219151与癫痫风险的关联。Pubmed的数据库,奥维德,WebofScience,搜索了中国国家知识基础设施。使用固定或随机效应模型计算汇总比值比(OR)和95%置信区间(CI)以评估多态性与癫痫风险之间的关联。进行试验序贯分析(TSA)以评估荟萃分析的结果。在亚洲和阿拉伯人群中,GABRA1rs2279020和GABRA6rs3219151与癫痫风险之间没有显着关联。当比较GABRA1rs2279020和GABRA6rs3219151多态性与抗癫痫药物反应性时,也观察到阴性结果。试验序贯分析证实了荟萃分析的结果。这项荟萃分析表明,在亚洲和阿拉伯人群中,GABRA1rs2279020和GABRA6rs3219151不是癫痫病因和抗癫痫药物反应性的危险因素。
The γ-aminobutyric acid type A receptors (GABAAR) have been reported to contribute to the pathogenesis of epilepsy and the recurrence of chronic seizures. Genetic polymorphisms in GABRA1 and
GABRA6 may confer a high risk of epilepsy and multiple drug resistance, but with conflicting results. We aimed to assess the association of GABRA1 rs2279020 and
GABRA6 rs3219151 with epilepsy risk using a meta-analysis. The databases of Pubmed, Ovid, Web of Science, and China National Knowledge Infrastructure were searched. Summary odds ratios (ORs) and 95% confidence intervals (CIs) were computed to evaluate the association between the polymorphisms and epilepsy risk using a fixed- or random-effect model. Trial sequential analysis (TSA) was performed to assess the results of the meta-analysis. No significant association between the GABRA1 rs2279020 and
GABRA6 rs3219151 and the risk of epilepsy was found in the Asian and Arabic populations. The negative results were also observed when comparing the GABRA1 rs2279020 and
GABRA6 rs3219151 polymorphism to antiepileptic drug responsiveness. The trial sequential analysis confirmed the results of the meta-analysis. This meta-analysis suggests that GABRA1 rs2279020 and
GABRA6 rs3219151 are not risk factors for the etiology of epilepsy and antiepileptic drug responsiveness in the Asian and Arabic populations.